Is gliclazide a sulfonylurea with difference? A review in 2016

References

• Brunton LL, Chabner BA, Knollmann BC, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 12th ed. New York (NY): McGraw-Hill Professional, The McGraw-Hill Companies, Inc.; 2010.
   Google Scholar
• Sola D, Rossi L, Schianca GP, et al. State of the art paper Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;4(4):840–848.
   Web of Science ®Google Scholar
• Proks P, Reimann F, Green N, et al. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002;51:S368–S376.
   PubMed Web of Science ®Google Scholar
• Baczko I, Husti Z, Lang V, et al. Sarcolemmal KATP channel modulators and cardiac arrhythmias. Curr Med Chem. 2011;18:3640–3661.
   PubMed Web of Science ®Google Scholar
• Mocanu MM, Maddock HL, Baxter GF, et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001;103:3111–3116.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Zhang H, Khaliulin I, et al. Activation of glibenclamide-sensitive ATP-sensitive K+ channels during β-adrenergically induced metabolic stress produces a substrate for atrial tachyarrhythmia. Circulation. 2012;5:1184–1192.
   PubMed Web of Science ®Google Scholar
• Abdelmoneim AS, Hasenbank SE, Seubert JM, et al. Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes Metab. 2012;14:130–138.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–1379.
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic Conditions (UK). Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). National Institute for Health and Clinical Excellence: Guidance. London: Royal College of Physicians, 2008.
   Google Scholar
• Rutten GEHM, De Grauw WJC, Nijpels G, et al. NHG-standaard diabetes mellitus type 2 (derde herziening). Huisarts Wet. 2013;56:512–525. [in Dutch]
   Google Scholar
• WHO. 19th expert committee on the selection and use of essential medicines. World Health Organization; 2013 [updated 2013 Apr 8–12; cited 2015 Dec 31]. Available from: http://www.who.int/selection_medicines/committees/expert/19/reviews/Glibenclamide_Rev2. pdf?ua=1.
   Google Scholar
• Hosker JP, Rudenski AS, Burnett MA, et al. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism. 1989;38:767–772.
   PubMed Web of Science ®Google Scholar
• Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complicat. 2003;17:11–15.
   PubMed Web of Science ®Google Scholar
• Monami M, Luzzi C, Lamanna C, et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev. 2006;22(6):477–482.
   PubMed Web of Science ®Google Scholar
• Monami M, Balzi D, Lamanna C, et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev. 2007;23:479–484.
   PubMed Web of Science ®Google Scholar
• Horsdal HT, Johnsen SP, Søndergaard F, et al. Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: apopulation-based follow-up study. Diabetes Metab Res Rev. 2009;25:515–522.
   PubMed Web of Science ®Google Scholar
• Khalangot M, Tronko M, Kravchenko V, et al. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract. 2009;86:247–253.
   PubMed Web of Science ®Google Scholar
• Pantalone KM, Kattan MW, Yu C, et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care. 2010;33:1224–1229.
   PubMed Web of Science ®Google Scholar
• Zeller M, Danchin N, Simon D, et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab. 2010;95:4993–5002.
   PubMed Web of Science ®Google Scholar
• Jørgensen CH, Gislason GH, Andersson C, et al. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention–a retrospective nationwide cohort study. Cardiovasc Diabetol. 2010;9:54.
   PubMed Web of Science ®Google Scholar
• Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32:1900–1908.
   PubMed Web of Science ®Google Scholar
• Andersson C, Gislason GH, Jorgensen CH, et al. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. Diabetes Res Clin Pract. 2011;94:119–125.
   PubMed Web of Science ®Google Scholar
• Pantalone KM, Kattan MW, Yu C, et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab. 2012;14(9):803–809.
   PubMed Web of Science ®Google Scholar
• Bo S, Castiglione A, Ghigo E, et al. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients. Eur J Endocrinol. 2013;169:117–126.
   PubMed Web of Science ®Google Scholar
• Abdelmoneim AS, Eurich DT, Gamble JM, et al. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study. Diabetes Obes Metab. 2014;16(1):22–29.
   PubMed Web of Science ®Google Scholar
• Lee YH, Lee CJ, Lee HS, et al. Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice. Diabetes Metab. 2015;41(3):208–215.
   PubMed Web of Science ®Google Scholar
• Simpson SH, Lee J, Choi S, et al. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2015;3(1):43–51.
   PubMed Web of Science ®Google Scholar
• Gram J, Jespersen J. Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients. Am J Med. 1991;90:S62–S66.
   Google Scholar
• Sliwinska A, Rogalska A, Szwed M, et al. Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells. Mol Biol Rep. 2012;39:5253–5267.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012;60:850–886.
   PubMed Web of Science ®Google Scholar
• Baba S, Nakagawa S, Takebe K, et al. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes. Tohoku J Exp Med. 1983;141(Suppl):693–706.
   PubMedGoogle Scholar
• Shaw KM, Wheeley MS, Campbell DB, et al. Home blood glucose monitoring in non-insulin-dependent diabetics: the effect of gliclazide on blood glucose and weight control, a multicentre trial. Diabetic Med. 1985;2:484–490.
   PubMed Web of Science ®Google Scholar
• Harrower AD. Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas. Curr Med Res Opin. 1985;9:676–680.
   PubMed Web of Science ®Google Scholar
• Jerums G, Murray RM, Seeman E, et al. Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study. Diabetes Res Clin Pract. 1987;3:71–80.
   PubMedGoogle Scholar
• Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care. 1989;12(3):203–208.
   PubMed Web of Science ®Google Scholar
• Harrower ADB, Wong C. Comparison of secondary failure rate between three second generation sulphonylureas. Diabetes Res. 1990;13:19–21.
   PubMedGoogle Scholar
• Harrower AD. Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM. Diabetes Res Clin Pract. 1991;14(Suppl 2):S65–S67.
   Google Scholar
• Satoh J, Takahashi K, Takizawa Y, et al. Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide. Diabetes Res Clin Pract. 2005;70:291–297.
   PubMed Web of Science ®Google Scholar
• Maedler K, Carr RD, Bosco D, et al. Sulfonylurea induced β-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 2005;90:501–506.
   PubMed Web of Science ®Google Scholar
• Tessier D, Dawson K, Tetrault JP, et al. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med. 1994;11:974–980.
   PubMed Web of Science ®Google Scholar
• van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol. 1997;50(6):735–741.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004;34:535–542.
   PubMed Web of Science ®Google Scholar
• Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab. 2005;7:722–728.
   PubMed Web of Science ®Google Scholar
• Inukai K, Watanabe M, Nakashima Y, et al. Efficacy of glimepiride in Japanese type 2 diabetic subjects. Diabetes Res Clin Pract. 2005;68(3):250–257.
   PubMed Web of Science ®Google Scholar
• Harrower AD. Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf. 2000;22(4):313–320.
   PubMed Web of Science ®Google Scholar
• Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007;30(2):389–394.
   PubMed Web of Science ®Google Scholar
• Collier A, Watson HH, Patrick AW, et al. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabete Metab. 1989;15:420–425.
   PubMed Web of Science ®Google Scholar
• Noury J, Nandeuil A. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. Diabete Metab. 1991;17:209–212.
   PubMed Web of Science ®Google Scholar
• Tessier D, Maheux P, Khalil A, et al. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism. 1999;48:897–903.
   PubMed Web of Science ®Google Scholar
• Guvener N, Gedik O. Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients. Acta Diabetol. 1999;36:93–97.
   PubMed Web of Science ®Google Scholar
• Salman S, Salman F, Satman I, et al. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. Curr Med Res Opin. 2001;16:296–306.
   PubMed Web of Science ®Google Scholar
• Furlong NJ, Hulme SA, O’Brien SV, et al. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents. Diabet Med. 2003;20:935–941.
   PubMed Web of Science ®Google Scholar
• Ristic S, Collober-Maugeais C, Pecher E, et al. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabet Med. 2006;23:757–762.
   PubMed Web of Science ®Google Scholar
• Comparison of repaglinide and gliclazide in Chinese subjects with Type 2 diabetes never received oral antidiabetic drug treatment. 2010. Available from: http://clinicaltrialsgov/ct2/show/NCT01022762?term=NCT01022762&rank=1.
   Google Scholar
• Lawrence JM, Reid J, Taylor GJ, et al. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early Type 2 diabetes. Diabetes Care. 2004;27:41–46.
   PubMed Web of Science ®Google Scholar
• Charbonnel BH, Matthews DR, Schernthaner G, et al. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med. 2005;22:399–405.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Charbonnel BH, Hanefeld M, et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005;21:167–174.
   PubMed Web of Science ®Google Scholar
• Perriello G, Pampanelli S, Di Pietro C, et al. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes. Diabet Med. 2006;23:246–252.
   PubMed Web of Science ®Google Scholar
• Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with Type 2 diabetes. Horm Metab Res. 2009;41:905–909.
   PubMed Web of Science ®Google Scholar
• Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabetic Med. 2010;27:318–326.
   PubMed Web of Science ®Google Scholar
• Landman GWD, de Bock GH, van Hateren KJJ, et al. Safety and efficacy of gliclazide as treatment for Type 2 diabetes: a systematic review and meta-analysis of randomized trials. PLoS ONE. 2014;9(2):e82880. doi:10.1371/journal.pone.0082880.
   PubMed Web of Science ®Google Scholar
• Schopman JE, Simon ACR, Hoefnagel SJM, et al. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2014;30:11–22.
   PubMed Web of Science ®Google Scholar
• Devendra D, Gohel B, Bravis V, et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract. 2009;63(10):1446–1450.
   PubMed Web of Science ®Google Scholar
• Zargar AH, Siraj M, Jawa AA, et al. Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast. Int J Cin Pract. 2010;64(8):1090–1094.
   PubMed Web of Science ®Google Scholar
• Aravind SR, Al Tayeb K, Ismail SB, et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study. Curr Med Res Opin. 2011;27(6):1237–1242.
   PubMed Web of Science ®Google Scholar
• Hassanein M, Hanif W, Malik W, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin. 2011;27(7):1367–1374.
   PubMed Web of Science ®Google Scholar
• Al-Arouj M, Hassoun AA, Medlej R, et al. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study. Int J Clin Pract. 2013;67(10):957–963.
   PubMed Web of Science ®Google Scholar
• Al Sifri S, Basiounny A, Echtay A, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011;65(11):1132–1140.
   PubMed Web of Science ®Google Scholar
• Aravind SR, Ismail SB, Balamurugan R, et al. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Curr Med Res Opin. 2012;28(8):1289–1296.
   PubMed Web of Science ®Google Scholar
• Hassanein M, Abdallah K, Schweizer A. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc Health Risk Manag. 2014;10:319–326.
   PubMedGoogle Scholar
• Mbanya JC, Al-Sifri S, Abdel-Rahim A, et al. Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP- 4 inhibitors during Ramadan: a meta-analytical approach. Diabetes Res Clin Pract. 2015;109:226–232. doi:10.1016/j.diabres.2015.04.030.
   PubMed Web of Science ®Google Scholar
• University Group Diabetes Program. A study of the eff ects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes. 1970;19(Suppl 2):747–830.
   Google Scholar
• UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• Olsson J, Lindberg G, Gottsäter M, et al. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia. 2000 May;43(5):558–560.
   PubMed Web of Science ®Google Scholar
• Mannucci E, Monami M, Masotti G, et al. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev. 2004;20(1):44–47.
   PubMed Web of Science ®Google Scholar
• Evans JM, Ogston SA, Emslie-Smith A, et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006 May;49(5):930–936.
   PubMed Web of Science ®Google Scholar
• Tzoulaki I, Nolokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. Bmj. 2009;339:b4731.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Majumdar SR, Simpson SH, et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002;25(12):2244–2248.
   PubMed Web of Science ®Google Scholar
• Gulliford M, Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev. 2004 May-Jun;20(3):239–245.
   PubMed Web of Science ®Google Scholar
• Sillars B, Davis WA, Hirsch IB, et al. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study. Diabetes Obes Metab. 2010 Sep;12(9):757–765.
   PubMed Web of Science ®Google Scholar
• Pantalone KM, Kattan MW, Yu C, et al. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis. Diabet Med. 2012;29(8):1029–1035.
   PubMed Web of Science ®Google Scholar
• Rao AD, Kuhadiya N, Reynolds K, et al. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: A meta-analysis of observational studies. Diabetes Care. 2008 Aug;31(8):1672–1678.
   PubMed Web of Science ®Google Scholar
• Johnsen SP, Monster TB, Olsen ML, et al. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther. 2006;13(2):134–140.
   PubMedGoogle Scholar
• Sadikot SM, Mogensen CE. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. Diabetes Res Clin Pract. 2008;82(3):391–395.
   PubMed Web of Science ®Google Scholar
• Arruda-Olson AM, Patch RK, Leibson CL, et al. Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction. Mayo Clinic Proceedings. 2009;84:28–33.
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Shah BR, et al. Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population. Diabet Med. 2012;29(12):1524–1528.
   PubMed Web of Science ®Google Scholar
• Nagendran J, Oudit GY, Bakal JA, et al. Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes? Diabetes Obes Metab. 2013;15:1022–1028.
   PubMed Web of Science ®Google Scholar
• Huang Y, Abdelmoneim AS, Light P, et al. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. J Diabetes Complications. 2015;29(2):196–202.
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
   PubMed Web of Science ®Google Scholar
• Zoungas S, De Galan BE, Ninomiya T, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care. 2009;32(11):2068–2074.
   PubMed Web of Science ®Google Scholar
• [ cited 2016 Jan 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT01794143?term=GRADE+study&rank=2
   Google Scholar
• Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res. 2013;10(4):289–301.
   PubMed Web of Science ®Google Scholar
• Vaccaro O, Masulli M, Bonora E, et al. TOSCA.IT study group. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutr Metab Cardiovasc Dis. 2012;22(11):997–1006.
   PubMed Web of Science ®Google Scholar